Feed
RSSLatest stories
Fresh from the newsroom. Prefer your reader? Grab the RSS feed.
Last updated July 20, 2026
- Public Health & Environment Sep 14, 2026 3 min read
9/11 Dust Exposure: New Columbia Study Reveals Latency Risk for COPD
Columbia researchers found 47% of 9/11 first responders developed COPD-like obstructive lung disease 25+ years after exposure. Here's the screening protocol and prevention strategies.
- Insurance & Policy Sep 14, 2026 3 min read
ACA Subsidy Rebates 2026: The $500 Trump Plan Explained
The Trump administration's FY27 budget proposes a flat $500 rebate for ACA marketplace enrollees. We break down who qualifies, how much you'll save, and what it means for dental and vision riders.
- Mental Health Sep 14, 2026 3 min read
AI Mental Health Chatbots: Accuracy Tested in Landmark USC Study
A benchmark study found AI chatbots misdiagnose depression 32% of the time. Here's when to trust them and when to insist on human care.
- Metabolic & Diabetes Sep 14, 2026 3 min read
Compounded GLP-1 Update: What September 2026 FDA Actions Mean for Patients
The FDA issued new guidance on compounded GLP-1 drugs after citing pharmacies for misbranded products. Here's what patients need to know about safety and legal alternatives.
- Sleep Medicine Sep 14, 2026 3 min read
CPAP Mask Leak Fixes That Actually Work: 2026 Tested Solutions
Struggling with CPAP mask leaks? These 3 community-tested fixes—including third-party cushions under $50—stop air escape and improve sleep quality. Includes fitting checklist.
- Public Health & Environment Sep 14, 2026 3 min read
Living Near Data Centers: Air Pollution Risks You Didn't Know About
New ProPublica investigation finds elevated NO₂ and asthma rates near data center clusters in Northern Virginia. Learn about diesel emissions, mitigation strategies, and whether your home is at risk.
- Insurance & Policy Sep 14, 2026 3 min read
Health-Care Costs Spiking: Employers Face 8.5% Increase in 2026
Employer health-care premiums rose 8.5% in 2026 — driven largely by GLP-1 weight-loss drugs topping $1,200/month. Here's how companies are adapting and what employees should know.
- Longevity & Aging Sep 14, 2026 3 min read
Epigenetic Editing Reverses Cellular Aging in Landmark Human Trial
A Columbia/Alkahest collaboration using CRISPRoff epigenetic editing reversed cellular aging markers in older adults. Here's what the Nature Medicine trial shows — and what it means for healthy longevity.
- Infectious Disease Sep 14, 2026 3 min read
Long COVID Pacing Tracker: How to Map Your Energy With the Crash Curve
Forget fixed rest schedules. New data-driven pacing lets long-haulers track exertion against symptom spikes using wearable metrics. Here's how to implement it.
- Cardiology Sep 14, 2026 3 min read
Lp(a) Drug Failure: Why Pelacarsen Didn’t Work and What’s Next
Novartis discontinues pelacarsen after Phase 3 trial showed no cardiovascular benefit. Learn why this Lp(a)-lowering drug failed and what novel RNA therapies are coming next.
- Infectious Disease Sep 14, 2026 3 min read
Measles Outbreak 2026: Pennsylvania Cluster Raises Vaccine Hesitancy Concerns
A measles outbreak in Pennsylvania has infected 27 people as vaccine hesitancy rises in three states. Here's where the cases are concentrated and what it means for public health.
- Women's Health Sep 14, 2026 3 min read
Menopause and ADHD: Why Brain Fog Gets Misdiagnosed
Menopause-related brain fog mimics ADHD in midlife women — causing misdiagnosis and inappropriate treatment. Here's how to tell the difference and what to do about it.
- Neurology & Sleep Sep 14, 2026 3 min read
Orzeyful: Inside Takeda’s New Narcolepsy Drug Winning FDA Priority Review
Orzeyful, Takeda's novel orexin-2 receptor agonist, shows 73% reduction in daytime sleep attacks in Phase 3. Learn how it differs from traditional stimulants and what the side-effect profile looks like.
- Cancer Care Sep 14, 2026 4 min read
Psilocybin for Chemo Neuropathy: Phase 3 Data Shows Significant Pain Relief
A Phase 3 trial finds psilocybin significantly reduces chemotherapy-induced peripheral neuropathy pain. Learn about dosing protocols, side effects, and when this treatment might become available.
- Preventative Health & Longevity Sep 2, 2026 8 min read
Why Your Prostate Medication Stopped Working After Years, and What Comes Next in 2026
Roughly half of men on BPH drugs see their symptoms return after years of control. The 2026 procedural ladder — UroLift, Rezum, water vapor, PAE, and the newer iTind — has matured into a real set of options that work better than medications and avoid the sexual side effects of traditional surgery.
- Sleep & Respiratory Health Sep 2, 2026 8 min read
Why Your CPAP Mask Stops Fitting Two Hours After You Fall Asleep — and the Real Fix
The most common CPAP complaint is that the mask fits when you put it on but leaks by hour two. The cause is jaw relaxation during deep sleep, not the mask itself. Here is the 2026 fix ladder: chin strap, hybrid mask, mouth taping, and a new European pill that may change everything.
- Public Health & Environment Sep 2, 2026 7 min read
Why a $480,000-a-Year Pancreatic Cancer Pill Just Doubled Survival — and Who Can Actually Get It
The FDA approved daraxonrasib in August 2026, and patients in the pivotal trial lived twice as long as those on chemo. The price tag, however, is roughly $480,000 a year. Here is who qualifies, how the drug works, and what the cost really means.
- Women's Health & Longevity Sep 2, 2026 7 min read
Why Your Estradiol Patch Suddenly Stopped Working — the 2026 Shortage and the Brand-Switch Trap
A nationwide estradiol patch shortage has pushed pharmacies to substitute Dotti, Sandoz, and Mylan generics, and thousands of women are reporting migraines, hot-flash returns, and breakthrough bleeding. Here is what's happening, what to ask for at the pharmacy, and what the alternatives are.
- Public Health & Environment Sep 2, 2026 8 min read
Why the FDA's New Commissioner Pick Could Change Your Prescriptions in 90 Days
President Trump nominated Dr. Heidi Overton, a top domestic policy aide and MAHA-aligned abortion opponent, to be the next FDA Commissioner. If confirmed, she will inherit a backlog of decisions on supplements, GLP-1 compounding, and pediatric vaccines. Here is what is likely to change and what is not.
- Cardiovascular Health Sep 2, 2026 7 min read
One-Time Gene Editing Cut LDL Cholesterol in Half for a Year — and It's Not a Pill
A small CRISPR Therapeutics trial dropped LDL by roughly 50 percent with a single infusion, and the effect held for a full year. Here is how in-body gene editing differs from statins, enlicitide, and inclisiran, who could qualify, and what the long-term unknowns are.